Search Results (124)

Background and Objectives: The usefulness of extracorporeal membrane oxygenation (ECMO) therapy for acute respiratory distress syndrome (ARDS) in patients with traumatic brain injury (TBI), spontaneous intracerebral hemorrhage (ICH), or subarachnoid hemorrhage (SAH) is limited. This study aimed to investigate the survival benefit of ECMO in ARDS that developed during hospitalization in high-risk neurological patients. Materials and Methods: This retrospective study evaluated patients with TBI or spontaneous ICH and SAH admitted to our hospital’s neurosurgery intensive care unit and who received ECMO therapy for ARDS between March 2017 and March 2024. Clinicodemographic characteristics, indications for and methods of ECMO application, occurrence of comorbidities, hospital survival rates, and ECMO weaning success rates were compared between survivors and non-survivors. Results: Among the 16 patients evaluated, seven (43.8%) were successfully discharged. The mean ages of the survivor and non-survivor groups were 52.1 and 58.6 years, respectively. The PaO₂/FiO₂ ratio pre-ECMO was similar in both groups (66.6 vs. 69.2); however, it improved significantly post-ECMO in the survivor group (264.1 vs. 209.4). The ECMO success rate was 100% in the survivor group and only 33.3% in the non-survivor group. The intensive care unit and hospital lengths of stay were longer in the survivor group. Most patients received veno-venous ECMO, and hemorrhagic complications were rare. Conclusions: ECMO for ARDS in patients with severe TBI or spontaneous ICH and SAH positively impacts survival and functional recovery and may be a beneficial treatment modality. Full article

Background: Early reports highlighted unique features of COVID-19-associated ARDS. The combination of prone position (PP) and positive end-expiratory pressure (PEEP)-induced lung recruitment maneuver (LRM) has demonstrated efficacy in enhancing oxygenation and improving outcomes in patients with ARDS, but it remains unknown whether there is a difference between COVID-19 ARDS and non-COVID-19 ARDS. Method: This study is a secondary analysis of a previously conducted randomized controlled trial. Patients with moderate to severe ARDS were consecutively enrolled during the study period (June–December 2023). After initiation of PP, patients received a PEEP-induced LRM followed by 12 h of daily PP. The interventions were repeated at least three times over the subsequent 3 days. Clinical outcomes, respiratory mechanics, and electrical impedance tomography (EIT) results were evaluated. Results: Twenty-eight patients were included in the final analysis, half of whom were infected with COVID-19 (50%). The PEEP-induced LRM led to greater improvement in oxygenation among COVID-19 ARDS than non-COVID-19 ARDS (∆PaO₂/FiO₂ ratio 90.5 mmHg vs. 65.5 mmHg, p < 0.05). Based on EIT measurement, compared with the non-COVID-19 ARDS group, PEEP-induced LRM resulted in a greater increase in ventilation distribution, mainly in the dorsal regions of interest 4 (ROI 4) ventilation distribution (∆ROI4 4.5% vs. 1.0%, p = 0.01) and in dorsal regional ventilation (∆dorsal regional ventilation 10.0% vs. 5.5%, p = 0.04) in the COVID-19 ARDS group. Conclusions: Compared to typical ARDS, PEEP-induced LRM combined with PP may be more effective in enhancing oxygenation in COVID-19-related ARDS. Full article

Background: Noble gases, such as argon, have been observed to exhibit cytoprotective effects. The non-anesthetic properties, abundance, and cost-effectiveness of argon suggest its clinical potential. While its efficacy in mitigating ischemia–reperfusion injury has been demonstrated in cellular and small animal models, data on its effects in large animals remain limited. This study evaluated the effects of argon inhalation on pulmonary ischemia–reperfusion injury in miniature swine with potential applications in transplantation. Methods: The left bronchial and pulmonary artery and veins were clamped for 90 min, and then the clamps were released to induce lung ischemia–reperfusion injury in 10 CLAWN miniature swine. The argon group (n = 5) inhaled a mixture of 30% oxygen and 70% argon for 360 min, whereas the control group (n = 5) inhaled a mixture of 30% oxygen and 70% nitrogen for an equivalent duration. Lung function was evaluated using chest X-ray, lung biopsies, and blood gas analysis. Results: The PaO₂/FiO₂ ratio significantly decreased in the control group 2 h post-reperfusion (568 ± 12 to 272 ± 39 mmHg), but was better preserved in the argon group (562 ± 17 to 430 ± 48 mmHg). Blood gas from the left pulmonary vein showed a superior PvO₂/FiO₂ ratio in the argon group (331 ± 40 vs. 186 ± 17 mmHg at 2 h; 519 ± 19 vs. 292 ± 33 mmHg at 2 days). Chest X-ray revealed reduced infiltration in the left lung. The lung biopsy histological scores improved in the argon group at 2 h and 2 days. Serum superoxide dismutase analysis and tissue TUNEL assays suggested that antioxidant and anti-apoptotic mechanisms, respectively, were involved. Conclusions: Perioperative argon inhalation attenuates ischemia–reperfusion injury in swine lungs, likely via anti-apoptotic and antioxidant effects. Full article

Background: Discontinuing mechanical ventilation during cardiopulmonary bypass (CPB) is common but may adversely affect postoperative pulmonary function. This study aimed to evaluate the impact of stopping ventilation during CPB on postoperative gas exchange, radiographic findings, intensive care unit (ICU) length of stay (LOS), mortality, reintubation, re-exploration, and bleeding. Methods: A prospective observational study was performed involving adult patients scheduled for elective cardiac surgery requiring CPB. Participants were divided into ventilated and non-ventilated groups according to intraoperative strategy. Postoperative arterial carbon dioxide levels (PaCO₂), arterial partial pressure of oxygen (PaO₂), the PaO₂/FiO₂ ratio (P/F ratio), arterial oxygen saturation (SaO₂), and the ratio of PaCO₂ to minute ventilation (PaCO₂/MV) were measured before the induction of anesthesia (within 5 min after transportation into the operating room), postoperatively within 5–10 min after transportation to the ICU, and in a 24 h postoperative period. Chest X-ray data, mechanical ventilation time, LOS in ICU, re-exploration, reintubation, and bleeding parameters were documented. Analyses were also conducted with the estimation of the age effect and BMI. Results: Individuals in the non-ventilated group exhibited lower postoperative P/F ratios and elevated postoperative PaCO₂ and PaCO₂/MV ratios. The difference in gas exchange leveled off within 24 h. There was no difference in the incidence of atelectasis (postoperatively in a 24 h period), mechanical ventilation time, LOS in ICU, or mortality. However, the incidence of bleeding was higher in the non-ventilated group (χ² = 5.78, p = 0.016). Interestingly, postoperative PaCO₂ and PaCO₂/MV peaked in the 50-year age group. Conclusions: Continued mechanical ventilation during CPB correlates with better postoperative gas exchange, better CO₂ clearance, and fewer bleeding events. The results suggest that maintaining low tidal volume ventilation during CPB may provide benefits, especially for patients aged 50 years. Full article

Background/Objectives: Treatment of severe traumatic brain injury (TBI) remains a major challenge in neurocritical care. The functional state of the brain largely depends on the applied ventilation strategy. Many patients develop acute respiratory distress syndrome (ARDS), for which lung-protective ventilation is recommended. However, its effect on outcomes in severe TBI remains unclear. This study aimed to assess whether a lung-protective ventilation strategy improves short-term outcomes in patients with severe TBI complicated by ARDS. Methods: This multicenter retrospective study included patients with severe TBI and ARDS treated in three Ukrainian tertiary hospitals. Lung-protective ventilation was defined as the use of a low tidal volume and moderate positive end-expiratory pressure (PEEP). The primary endpoint was 28-day mortality; secondary endpoints included the Glasgow Coma Scale (GCS) score and intracranial pressure (ICP) on day 28. Univariate and multivariate logistic regression analyses identified factors associated with mortality. Results: Mortality did not depend on arterial PaO₂ (p = 0.173) but correlated with lower GCS (p < 0.001), reduced PaO₂/FiO₂ ratio (p < 0.001), higher tidal volume (p < 0.001), and lower PEEP (p < 0.001). Lung-protective ventilation reduced mortality from 78.6% to 31.4%. Conclusions: Lung-protective ventilation is safe and effective in severe TBI with ARDS, significantly improving short-term survival without compromising cerebral outcomes. Full article

Introduction: Prolonged prone positioning, exceeding 16 h, has been associated with reduced mortality among patients with moderate to severe acute respiratory distress syndrome (ARDS). Extending the duration of prone positioning may provide greater therapeutic benefits. This study aims to assess the clinical outcomes between 16 h and 24 h prone positioning therapy in patients with moderate to severe ARDS. Methods: This prospective randomized clinical trial was conducted in the intensive care unit of a university-affiliated tertiary medical center. Patients were randomly assigned to receive either 16 h or 24 h prone positioning therapy. All participants were managed according to a standardized protocol incorporating low tidal volume and protective lung strategies. Results: Out of 45 patients diagnosed with moderate to severe ARDS requiring mechanical ventilation, 21 were allocated to the 16 h prone positioning group and 24 were assigned to the 24 h group. There were no significant differences in PaO₂/FiO₂ ratios, driving pressure, or serum lactate levels between the two groups. The first session of prone positioning resulted in significantly greater PaO₂/FiO₂ improvement compared to the second session. The 24 h group showed a trend toward requiring fewer prone positioning sessions than the 16 h group. Secondary outcomes did not differ significantly between groups. Conclusions: Both 16 h and 24 h prone positioning therapies improved oxygenation in patients with moderate to severe ARDS. The 24 h prone group showed a trend toward fewer sessions, potentially reducing clinical workload. The first prone session provided greater oxygenation improvement compared to the second session. Full article

Background: Acute exacerbation (AE) of idiopathic inflammatory myopathy-associated interstitial lung disease (IIM-ILD) is fatal. Infection is one of the most important triggers of the AE of IIM-ILD. We evaluated the clinical features and prognosis of idiopathic (I-AE) and infection-triggered (iT-AE) acute exacerbation in IIM-ILD patients. Methods: We retrospectively reviewed 278 consecutive patients with IIM admitted to our hospital between January 2014 and December 2020. Among them, 69 patients experienced AE of IIM-ILD, including 34 with I-AE and 35 with iT-AE. Clinical features and short- and long-term outcomes were analyzed in this preliminary study. Results: Compared with I-AE, patients with iT-AE presented with lower hemoglobin and PaO₂/FiO₂ ratios but higher pulse, body temperature, white blood cell count, neutrophil percentage (NEU), C-reactive protein, erythrocyte sedimentation rates, lactate dehydrogenase, and hydroxybutyrate dehydrogenase levels. They also had more extensive ground-glass opacities (GGOs) on high-resolution computed tomography (all p < 0.05). Mortality was significantly higher in iT-AE than that in I-AE at 30 days (28.6% vs. 5.9%), 90 days (34.3% vs. 14.9%), and 1 year (54.3% vs. 17.6%; log-rank test, p = 0.002). Multivariate logistic regression showed that the combination of NEU and GGO extent could help discriminate iT-AE from I-AE (area under the receiver operating characteristic curve: 0.812; 95% confidence interval: 0.711–0.913; sensitivity: 71.4%, specificity: 73.5%, accuracy: 72.5%). Conclusion: This study found that iT-AE patients exhibited more severe hyperinflammation and markedly worse survival than I-AE patients. Combining NEU and GGO extent may assist in differentiating AE subtypes. Larger prospective studies are required to validate these findings. Full article

Aim: The rationale for combining various extracorporeal blood purification techniques to improve patient outcomes is currently being discussed extensively. The combined use of CytoSorb^®, with high capacity for cytokine removal, and Oxiris^®, which adsorbs endotoxins and smaller cytokines, may enhance the efficacy of blood purification in sepsis. Study Design: Retrospective analysis of efficacy and safety of simultaneous use of CytoSorb^® and Oxiris^® in 12 consecutive critically ill patients with COVID-19, who developed secondary bacterial sepsis and persistent hemodynamic instability. Results: Most of the patients (n = 8) treated with combination of the Oxiris^® and CytoSorb^® had a significant decrease in vasopressor requirement. Pre- and post-haemoadsorption data were analysed in 9 patients, who completed a 24 h course of treatment. A significant decrease in mean SOFA score (16.3 ± 1.7 to 15.0 ± 2.0 points), median vasopressor requirement (0.56 ± 0.29 to 0.11 ± 0.21 µg/kg/min), median procalcitonin levels (6.5 ± 27.0 to 1.6 ± 6.0 ng/mL), median IL-6 levels (584 ± 6279 to 107 ± 571 pg/mL), and mean leucocyte count (36.0 ± 20.6 to 20.9 ± 10.1 × 10³/mL) was observed. Furthermore, there was significant increase in PaO₂/FiO₂ ratio (108 ± 30 to 185 ± 55). We did not observe any device-associated adverse events or technical problems. A 27.5% drop in platelet count (269 ± 116 to 195 ± 82 × 10⁶/mL) and an 11.8% drop in haemoglobin level (10.7 ± 2.9 to 9.5 ± 2.0 g/dL) was noted. Conclusions: Our data suggests that combined use of Oxiris^® and CytoSorb^® for simultaneous cytokine and endotoxin removal in patients with underlying viral infection may be a promising therapeutic option. Our findings may serve as a guide for future research and provide directions for further development in this field. Full article

Background: Post-extubation hypoxaemia and postoperative pulmonary complications (PPCs) are common in surgical patients and contribute significantly to morbidity and prolonged recovery. High-flow nasal oxygen therapy (HFNOT) has been proposed as an alternative to conventional oxygen therapy (COT) in improving oxygenation and reducing PPCs postoperatively. Objectives: To evaluate the effectiveness of HFNOT compared to COT in reducing post-extubation hypoxaemia and PPCs in adult surgical patients, and to assess its impact on other clinical outcomes including ICU and hospital length of stay, mortality, and the need for escalation of respiratory support. Methods: A systematic review and meta-analysis of randomized controlled trials was conducted following PRISMA guidelines. Studies were identified from five databases including PubMed, Scopus, EBSCOHost, ProQuest, Ovid MEDLINE and Web of Science. Adult postoperative patients who received HFNOT after extubation were compared to those receiving COT. Primary outcomes included PaO₂/FiO₂ (PF) ratio and incidence of PPCs. Secondary outcomes were hospital and ICU length of stay, mortality, and need for escalation of therapy. Results: Seventeen trials comprising 1830 patients were included. HFNOT significantly improved PF ratio post-extubation and reduced the incidence of hypoxaemia and PPCs compared to COT. For secondary outcomes, HFNOT was associated with a reduced hospital length of stay and lower postoperative mortality, while no significant difference was found for ICU stay. Escalation of respiratory support was more frequent in the COT group. Subgroup analyses indicated greater improvements in oxygenation with HFNOT of shorter duration (<24 h) and in non-cardiothoracic patients. Conclusions: HFNOT is associated with improved postoperative oxygenation and a reduction in respiratory complications following extubation in surgical patients. The most pronounced benefits were observed in non-cardiothoracic populations and with short-duration applications. While the beneficial effects of HFNOT appear consistent across the included randomized controlled trials, further large-scale studies with standardized intervention durations, surgical populations, and clearly defined criteria for escalation of therapy are needed to strengthen and confirm these findings. Full article

Background and Objectives: Despite the devastating impact of acute exacerbations of fibrotic interstitial lung diseases (AE-fILDs), established treatment strategies are majorly lacking. The therapeutic potential of intravenous immunoglobulin (IVIG) in AE-fILDs was explored considering its anti-inflammatory and immunomodulatory effects, as well as the immunocompromised status of fILD patients and the high frequency of infections that AE-fILDs triggers. Materials and Methods: This was an observational, retrospective study. We investigated the therapeutic potential of IVIG in patients hospitalized for AE-fILDs between May 2021 and November 2024. Results: We included 39 patients diagnosed with AE-fILDs. All patients received IVIG (total dose of 1 g/kg, divided into three daily doses), pulse corticosteroids for three days and broad-spectrum antibiotics. No adverse events were considered to be related to IVIG therapy during the study period. The in-hospital and the 90-day mortality were 10 (26%) and 13 (33%) patients, respectively. Twenty-nine patients (74%) were discharged and 18 of them (62%) were in need of long-term oxygen therapy. The mean PaO₂/FiO₂ ratio (P/F ratio) was 183 mmHg on admission and 294 mmHg on discharge (t-test, p < 0.0001). Conclusions: This study suggests a potential therapeutic signal, indicating that IVIG is a relatively harmless, well-tolerated, and a potentially effective add-on treatment to current therapeutic approaches. Further research is essential to clarify the role of IVIG, determine optimal treatment protocols, and assess its efficacy in different ILD subtypes. Full article

Background/Objectives: To evaluate the safety and feasibility of continuous positive airway pressure (CPAP) in patients with acute myocardial infarction (AMI) and acute decompensated heart failure (ADHF) during percutaneous coronary intervention (PCI). Non-invasive ventilation (NIV) is an established treatment for ADHF. Methods: All consecutive patients admitted to Santa Croce Hospital of Cuneo, receiving CPAP for ADHF in the cath lab during PCI for AMI, were included in a case series. Results: Between December 2018 and March 2021, 25 pts were included (median age 78 yrs, 48% female), with 64% of patients presenting with ST-elevation AMI and 17 (69%) in cardiogenic shock. At admission median left ventricular ejection fraction was 35 (20–60)% and eight (32%) patients had severe mitral regurgitation. Median PaO₂/FiO₂ was 183 (141–261) mmHg/%, lactate level 2.4 (1.3–3.8) mmol/L, and NTproBNP 7882 (3139–35,000) ng/L. CPAP was positioned and managed by nurses in all cases. Median FiO₂ was 50 (35–100)% and median positive end-expiratory pressure was 7.5 (5–12) cmH₂O. CPAP was generally well tolerated in 22 (88%) patients. One patient suffered cardiac arrest that led to CPAP interruption due to resuscitation maneuvers. No patient required orotracheal intubation in the cath lab. The post-procedural PaO₂/FiO₂ ratio substantially improved to 230 (175–356) mmHg/% (p = 0.007) and lactate decreased to 1.5 (1.0–1) mmol/L (p = 0.002). One patient died during hospital stay due to underlying disease, unrelated to the study procedure. Conclusions: CPAP during PCI in patients with AMI and ADHF seems feasible, safe, and well tolerated. Larger studies are warranted to confirm these results. Full article

Background/Objectives: Mechanical ventilation is essential in the management of acute respiratory failure (RF); however, prolonged use increases the risk of complications. Accurate predictors are therefore needed to guide timely weaning. The Rapid Shallow Breathing Index (RSBI), the dead space to tidal volume ratio (VD/VT), and the Integrative Weaning Index (IWI) are among the key indices used to assess weaning readiness. This study aimed to examine whether these indices differ between patients with Type 1 (hypoxemic) and Type 2 (hypercapnic) respiratory failure who were successfully extubated in the emergency department, in order to explore their physiologic variability across respiratory failure phenotypes. Methods: This cross-sectional study included 35 adult patients (23 with Type 1 RF, 12 with Type 2 RF) who were successfully weaned from mechanical ventilation in the Emergency Department of a tertiary care hospital between 2022 and 2024. RSBI, VD/VT, IWI, and arterial blood gas parameters were recorded. Descriptive and comparative statistical analyses were performed, with significance set at p < 0.05. Results: There were no significant differences in age, gender, or comorbidities between the groups. Type 2 RF patients had higher FiO₂ requirements (37.5% vs. 30.0%; p = 0.03) and PaCO₂ levels (49.1 ± 9.65 mmHg vs. 40.3 ± 4.49 mmHg; p < 0.001). The PaO₂/FiO₂ ratio was lower in the Type 2 group (169 ± 49.6) compared to the Type 1 group (244 ± 95.6; p = 0.017). VD/VT ratios were significantly higher in Type 2 RF patients (0.37 ± 0.04 vs. 0.29 ± 0.13; p = 0.046). RSBI values were identical between groups (40.0 in both; p = 1.00), and IWI values showed no significant difference (70.8 ± 30.7 vs. 79.3 ± 32.5; p = 0.45). Conclusions: Although RSBI and IWI values were similar across respiratory failure types, patients with Type 2 RF demonstrated higher VD/VT ratios and lower PaO₂/FiO₂, indicating reduced gas exchange and alveolar ventilation efficiency. These findings suggest that VD/VT may be a more useful parameter for assessing weaning readiness in hypercapnic patients. Full article

Background: Patients undergoing head and neck surgery with free flap reconstruction are at a high risk for postoperative respiratory complications, including hypoxemia. Conventional oxygen therapy (COT) and non-invasive ventilation (NIV) may be poorly tolerated or contraindicated due to anatomical limitations. High-Flow Nasal Cannula (HFNC) therapy represents a promising alternative, offering better humidification, comfort, and oxygenation. Methods: This retrospective single-center study included 50 adult patients admitted to the ICU after head and neck oncologic surgery with flap reconstruction from January 2022 to November 2024. All patients received HFNC immediately after extubation. Hypoxemia was defined as a PaO₂/FiO₂ (P/F) ratio of < 300 mm Hg. The primary outcome was the incidence of postoperative hypoxemia. Secondary outcomes included reintubation rates and patient compliance. Data were collected at 1, 6, 12, and 24 h following HFNC initiation. Results: Out of 59 patients screened, 9 were excluded per predefined criteria. Among the 50 included, only 2 patients (4%) developed hypoxemia, with P/F ratios remaining above 250. No patients required reintubation. The respiratory rate–oxygenation index (ROX index) improved steadily during the first 24 h. HFNC was well tolerated; only three patients required minor adjustments due to discomfort. Conclusions: HFNC use in the immediate postoperative period after head and neck surgery was associated with a low incidence of hypoxemia and no reintubations. These findings suggest that HFNC is a safe and effective strategy for postoperative respiratory support in this high-risk population. Further prospective studies are warranted to confirm the benefit of HFNC in reducing hypoxemia and preventing reintubation in high-risk surgical populations. Full article

Introduction: The combination of ceftazidime−avibactam (CAZ-AVI) with aztreonam (ATM) may be an option for the treatment of infections due to metallo-β-lactamases (MBLs) producing bacteria, as recommended by current guidelines. MBLs protect the pathogen from any available β-lactam/β-lactamase inhibitor (BL/BLI). Moreover, in vitro and clinical data suggest that double carbapenem therapy (DCT) may be an option for such infections. Materials and Methods: This retrospective study was conducted in two mixed intensive care units (ICUs) at the University Hospital of Larissa, Thessaly, Greece, and the General Hospital of Larissa, Thessaly, Greece, during a three-year period (2022−2024). Mechanically ventilated patients with bloodstream infection (BSI) caused by K. pneumoniae resistant to all BL/BLI combinations were studied. Patients were divided into three groups: in the first, patients were treated with CAZ-AVI + ATM; in the second, with DCT; and in the third, with antibiotics other than BL/BLIs that presented in vitro susceptibility. The primary outcome of the study was the change in Sequential Organ Failure Assessment (SOFA) score between the onset of infection and the fourth day of antibiotic treatment. Secondary outcomes were SOFA score evolution during the treatment period, total duration of mechanical ventilation (MV), ICU length of stay (LOS), and ICU mortality. Results: A total of 95 patients were recruited. Among them, 23 patients received CAZ-AVI + AZT, 22 received DCT, and 50 patients received another antibiotic regimen which was in vitro active against the pathogen. The baseline characteristics were similar. The mean (SE) overall age was 63.2 (1.3) years. Mean (SE) Acute Physiology and Chronic Health Evaluation II (APACHE II) and SOFA scores were 16.3 (0.6) and 7.6 (0.3), respectively. The Charlson Index was similar between groups. The control group presented a statistically lower SOFA score on day 4 compared to the other two groups [mean (SE) 8.9 (1) vs. 7.4 (0.9) vs. 6.4 (0.5) for CAZ-AVI + ATM, DCT and control group, respectively (p = 0.045)]. The duration of mechanical ventilation, ICU LOS, and mortality were similar between the groups (p > 0.05). Comparison between survivors and non-survivors revealed that survivors had a lower SOFA score on the day of BSI, higher PaO₂/FiO₂ ratio, higher platelet counts, and lower lactate levels (p < 0.05). Septic shock was more frequent among non-survivors (60.3%) in comparison to survivors (27%) (p = 0.0015). Independent factors for mortality were PaO₂/FiO₂ ratio and lactate levels (p < 0.05). None of the antibiotic regimens received by the patients was independently associated with survival. Conclusions: Treatment with CAZ-AVI + ATM or DCT may offer similar clinical outcomes for patients suffering from BSI caused by K. pneumoniae strains resistant to all available BL/BLIs. However, larger studies are required to confirm the findings. Full article

Background: In patients with COVID-19 pneumonia, the estimation of PaO₂ represents the method of choice for monitoring a patient’s oxygenation status and assessing disease severity. The aim of this study is, therefore, to investigate the correlation between SpO₂/FiO₂ and PaO₂/FiO₂, as well as radiological and laboratory biomarkers of severity. Methods: In this monocentric observational, analytical, retrospective large cohort study, consecutive patients with a confirmed diagnosis of pneumonia from SARS-CoV-2, hospitalized at the Cotugno Hospital—AORN dei Colli—of Naples, between 1 September 2020 and 28 February 2022 were considered for study inclusion. Patients with missing data were excluded. Results: We included 585 patients (median age 63 [22–95]). Mean PaO₂/FiO₂ was 203 [66–433], whilst mean SpO₂/FiO₂ was 240 [81–471]. We found that P/F ratio could be predicted from S/F ratio, as described by the linear regression equation (P/F = 13.273 + 0.790 × S/F). In addition, we found that SpO₂/FiO₂ ratio significantly correlated with HRCT score and laboratory markers of severity, including IL-6, D-Dimer, and NLR. Conclusions: SpO₂/FiO₂ ratio represents a highly useful resource as a valid surrogate of P/F ratio in patients with COVID pneumonia, also correlating with other biomarkers of severity, such as HRCT score and key laboratory markers. Full article